|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UNC5C |
Gene summary for UNC5C |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UNC5C | Gene ID | 8633 |
| Gene name | unc-5 netrin receptor C | |
| Gene Alias | UNC5H3 | |
| Cytomap | 4q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | A8K385 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8633 | UNC5C | male-WTA | Human | Thyroid | PTC | 4.22e-25 | 1.92e-01 | 0.1037 |
| 8633 | UNC5C | PTC01 | Human | Thyroid | PTC | 2.14e-10 | 9.23e-02 | 0.1899 |
| 8633 | UNC5C | PTC03 | Human | Thyroid | PTC | 1.63e-05 | 1.14e-01 | 0.1784 |
| 8633 | UNC5C | PTC04 | Human | Thyroid | PTC | 2.67e-06 | 1.80e-01 | 0.1927 |
| 8633 | UNC5C | PTC05 | Human | Thyroid | PTC | 5.46e-18 | 6.31e-01 | 0.2065 |
| 8633 | UNC5C | PTC06 | Human | Thyroid | PTC | 1.64e-17 | 5.30e-01 | 0.2057 |
| 8633 | UNC5C | PTC07 | Human | Thyroid | PTC | 4.09e-20 | 3.15e-01 | 0.2044 |
| 8633 | UNC5C | ATC4 | Human | Thyroid | ATC | 1.12e-03 | -7.78e-02 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Stomach | WIM |  |
| Stomach | SIM |  |
| Liver | NAFLD |  |
| Liver | Cirrhotic |  |
| Liver | HCC |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000724912 | Liver | HCC | I-kappaB kinase/NF-kappaB signaling | 156/7958 | 281/18723 | 6.66e-06 | 8.00e-05 | 156 |
| GO:004312312 | Liver | HCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 108/7958 | 186/18723 | 1.28e-05 | 1.43e-04 | 108 |
| GO:003109822 | Liver | HCC | stress-activated protein kinase signaling cascade | 138/7958 | 247/18723 | 1.43e-05 | 1.57e-04 | 138 |
| GO:005140322 | Liver | HCC | stress-activated MAPK cascade | 134/7958 | 239/18723 | 1.50e-05 | 1.64e-04 | 134 |
| GO:004312212 | Liver | HCC | regulation of I-kappaB kinase/NF-kappaB signaling | 138/7958 | 249/18723 | 2.47e-05 | 2.58e-04 | 138 |
| GO:007030222 | Liver | HCC | regulation of stress-activated protein kinase signaling cascade | 105/7958 | 195/18723 | 8.79e-04 | 5.20e-03 | 105 |
| GO:003287222 | Liver | HCC | regulation of stress-activated MAPK cascade | 102/7958 | 192/18723 | 1.86e-03 | 9.49e-03 | 102 |
| GO:000725412 | Liver | HCC | JNK cascade | 89/7958 | 167/18723 | 3.09e-03 | 1.44e-02 | 89 |
| GO:006156419 | Thyroid | PTC | axon development | 199/5968 | 467/18723 | 5.27e-07 | 8.53e-06 | 199 |
| GO:000740918 | Thyroid | PTC | axonogenesis | 178/5968 | 418/18723 | 2.17e-06 | 2.91e-05 | 178 |
| GO:006156423 | Thyroid | ATC | axon development | 220/6293 | 467/18723 | 6.85e-10 | 1.80e-08 | 220 |
| GO:000740919 | Thyroid | ATC | axonogenesis | 197/6293 | 418/18723 | 5.09e-09 | 1.13e-07 | 197 |
| GO:00074113 | Thyroid | ATC | axon guidance | 96/6293 | 227/18723 | 3.74e-03 | 1.63e-02 | 96 |
| GO:00974853 | Thyroid | ATC | neuron projection guidance | 96/6293 | 228/18723 | 4.36e-03 | 1.81e-02 | 96 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UNC5C | SNV | Missense_Mutation | rs777393565 | c.578G>C | p.Gly193Ala | p.G193A | O95185 | protein_coding | tolerated(0.06) | possibly_damaging(0.506) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | |
| UNC5C | SNV | Missense_Mutation | c.908N>C | p.Ser303Thr | p.S303T | O95185 | protein_coding | tolerated(0.12) | benign(0.025) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD | |
| UNC5C | SNV | Missense_Mutation | c.2101N>A | p.Val701Ile | p.V701I | O95185 | protein_coding | tolerated(0.07) | possibly_damaging(0.899) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| UNC5C | SNV | Missense_Mutation | c.1604N>T | p.Ser535Ile | p.S535I | O95185 | protein_coding | deleterious(0.03) | benign(0.301) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| UNC5C | SNV | Missense_Mutation | rs547179134 | c.2398N>T | p.Arg800Trp | p.R800W | O95185 | protein_coding | tolerated(0.27) | probably_damaging(0.993) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| UNC5C | SNV | Missense_Mutation | c.406N>C | p.Gly136Arg | p.G136R | O95185 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| UNC5C | SNV | Missense_Mutation | novel | c.838T>G | p.Tyr280Asp | p.Y280D | O95185 | protein_coding | deleterious(0.04) | benign(0.053) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| UNC5C | insertion | Nonsense_Mutation | novel | c.805_806insAAAAAGACTATATAAAATGCAGTTGAAAG | p.Trp269Ter | p.W269* | O95185 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| UNC5C | insertion | Nonsense_Mutation | novel | c.1175_1176insACTTTTTAACTTCTAATCGAAAAGAGT | p.Ala392_Ile393insLeuPheAsnPheTerSerLysArgVal | p.A392_I393insLFNF*SKRV | O95185 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| UNC5C | SNV | Missense_Mutation | novel | c.2700C>A | p.Asn900Lys | p.N900K | O95185 | protein_coding | deleterious(0) | benign(0.185) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |